Abdul Latif Jameel Health

Abdul Latif Jameel Health was founded in late 2020 by the Jameel family to address global disparities in access to modern medical care—especially across emerging markets. It operates as the healthcare arm of the diversified Abdul Latif Jameel group. The company focuses on accelerating access to innovative medical technologies—including digital health solutions, diagnostics, medtech devices, gene therapies for rare diseases, and select pharmaceuticals—primarily through strategic partnerships and acquisitions. Its business model centers on commercialization/distribution rather than internal R&D or proprietary product development. Recent milestones include acquiring a majority stake in Genpharm—a leader in rare diseases/gene therapy—and partnering with US-based Evelo Biosciences for regional development/commercialization of investigational oral medicines targeting inflammatory conditions like psoriasis and COVID‑19.